Therapy of superficial bladder carcinomas

Urologia Internationalis

Volumn 63, Issue 1, 1999, Pages 32-39

  Otto, T ^b   Krege, S ^c   Noll, F ^a   Rubben H ^c  

^a Knappschaftskrankenhaus Bardenberg   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c NONE

Author keywords

Bladder carcinoma; Progression; Recurrence; T1 G3 bladder carcinoma

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; DOXORUBICIN; MITOMYCIN C;

ADJUVANT THERAPY; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER IMMUNOTHERAPY; CYSTECTOMY; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MAINTENANCE THERAPY; PRIORITY JOURNAL; RECURRENCE RISK; TRANSURETHRAL RESECTION; TUMOR GROWTH;

EID: 0032748573     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030416     Document Type: Article

References (51)

1. RUTT (Registry for Urinary Tract Tumours: Harnwegstumorregister): Jahresbericht. Verh Dtsch Ges Urol 1985;37:665.
2. Malmström PU, Busch C, Norlen BJ: Recurrence, progression and survival in bladder cancer. Scand J Urol Nephrol 1987;21:185-195.
3. Carpinito GA, Vogelzang N, Hayden CL: Urinary nuclear matrix protein as a marker for carcinoma of the urinary tract. J Urol 1996;156: 1280-1285.
4. Sarosdy MF, Soloway MS, Blumenstein BA: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 1995;154:379-384.
5. Schmetter BS, Lamm DL, Grossman HB, Butman BR: Results of a multicenter trial evaluation of Aura-tek FDP. J Urol 1996;155:492A.
6. Friedrich G, Schwaibold H, Huland H: Detektion von LOH in P53-Gen bei Blasentumorpatienten in Tumor und Sediment mittels einfacher PCR-Technik. Akt Urol 1998;29:36.
7. Müller M, Heicappel R, Miller K: Nachweis von humaner Telomerase und von Telomeraseaktivität zur Diagnose von Harnblasentumoren. Akt Urol 1998;29:37.
8. Fradet Y, Cordon-Cardo C: Critical appraisal of tumour markers in bladder cancer. Semin Urol 1993;11:145-153.
9. Otto T, Bex A, Schmidt U, Raz A, Rübben H: Improved prognosis assessment for patients with bladder carcinoma. AJP 1997;150:1919-1923.
10. Babkowski RC, Katz RL, Dinney CPN: Angiogenesis does not have prognostic value in T1 bladder cancer. J Urol 1996;156:615A.
11. Bochner BH, Cote RJ, Nichols PW: Angiogenesis in bladder cancer. J Natl Cancer Inst 1995; 87:1603-1612.
12. Köhrmann KU, Woeste M, Rassweiler J, Alken P: Die transurethrale Nachresektion, notwendig beim oberflächlichen Blasenkarzinom. Urologe [A] 1992;31(suppl):A59.
13. Lamm DL, Blumenstein B, Sarosdy M, Grossmann HB, Crawford ED: Significant long-term patient benefit with BCG maintenance therapy. J Urol 1997;157:831.
14. Rübben H, Jocham D: Therapie des oberflächlichen Blasenkarzinoms. Urologe [A] 1991;30: 2-9.
15. Jakse G, Loidl W, Seeber G: Stage T1, grade 3 transitional cell carcinoma of the bladder: An unfavourable tumour. J Urol 1987;137:39-43.
16. Heney NM, Ahmed S, Flannagan MJ, et al: Superficial bladder cancer: Progression and recurrence. J Urol 1983;130:1083-1086.
17. Kaubisch S, Lum BL, Reese J, Freiha F, Torti FM: Stage T1 bladder cancer: Grade is the primary determinant risk of muscle invasion. J Urol 1991;146:28-31.
18. Althausen AF, Prout GR, Daly JJ: Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976;116: 575.
19. Rübben H, Lutzeyer W, Ebbinghaus KD, Dahm HH: Adjuvant radiotherapy in Ta, T1 and T2 bladder tumours after transurethral resection: A retrospective study. Prog Clin Biol Res 1984;162B:21-25.
20. van der Werf-Messing BHP, Hop WCJ: Carcinoma of the urinary bladder (category T1NXM0) treated either by radium implant or by transurethral resection only. Jnt J Radiat Oncol Biol Phys 1981;7:299-303.
21. Beisland HO, Seland P: A prospective randomized study on neody-??-YAG laser irradiation versus TUR in the treatment of urinary bladder cancer. Scand J Urol Nephrol 1986;20: 209.
22. Hall RR, Newling D, Ramsden PD, Richards B, Robinson MRD, Smith PH: Treatment of invasive bladder cancer by local resection and high dose methotrexate. Br J Urol 1984;56: 668-672.
23. Rübben H, Weissbach L, Knebel L, et al: Adjuvant systemic chemotherapy after complete transurethral resection of superficially invasive bladder carcinoma (T1 G3-4 and T2 G2-4). Urol Int 1990;45:78-83.
24. Pront GR Jr, Koontz WW Jr, Coombs LJ, Hawkins IR, Friedell GH: Long-term rate of 90 patients with superficial bladder cancer randomly assigned to receive or not receive thiotepa. J Urol 1983;130:677.
25. Green DF, Robinson MRG, Glashan R, Newling D, Dalesio O, Smith PH: Does intravesical chemotherapy present invasive bladder cancer. J Urol 1984;131:33.
26. Huland H, Otto U, Dröse M, Klöppel G: Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: Influence or recurrence, progression and survival. J Urol 1984;132:27.
27. MRC, London: The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer: A MRC study. Br J Urol 1985;57:680.
28. Rübben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W, Giani G: Natural history and treatment of low and high risk superficial bladder tumours. J Urol 1985;139:283-285.
29. Kurth KH, Sylvester R, De Pauw M, Ten Kate F: Intracavitary treatment of transitional cell carcinoma of the bladder: Questions and lesions after 27 years of experience. Prog Clin Biol Res 1989;310:125.
30. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, Meijden A, Parmar M, Bijneus L: A combined analysis of EORTC and MRC randomized trials for the prophylactic treatment of stage TA/1 bladder cancer. J Urol 1996;156: 1934-1941.
31. Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger CB, Pauw MD, Sylvester R: Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma. J Urol 1995;153:934-941.
32. Lamm DL: BCG vs adriamycin in the treatment of transitional cell carcinoma in situ: A Southwest Oncology Group study. J Urol 1985; 133:A283.
33. Debruyne FJG, van der Meyden PM: BCG versus mitomycin C intravesical therapy in patients with superficial bladder cancer: First results of a randomized prospective trial. J Urol 1987;137:179A.
34. Mori K, Lamm DL, Crawford ED: A trial of bacillus Calmette-Guérin versus adriamycin in superficial bladder cancer: A Southwest Oncology Group study. Urol Int 1996;322:1.
35. Jauhianinen K, Rintala E, Alfthan O: Immunotherapy (BCG) versus chemotherapy (MMC) in intravesical treatment of superficial bladder cancer; in de Kernion JB (ed): International Society of Urology Reports. Immunotherapy of Urological Tumours. Edinburgh, Churchill-Livingstone, 1990.
36. Martinez-Piniero JA, Jemenz Leon J, Martinez-Piniero L Jr, et al: Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: A randomized study in 202 patients with superficial bladder cancer. J Urol 1990;143:502.
37. Herr HW, Laudone VP: Intravesical therapy for superficial bladder cancer; in Vita VT Jr (ed): Cancer Principles and Practise of Oncology, ed 2. Philadelphia, Lippincott, 1988. pp 1-10.
38. Herr HW, Wartinger DD, Fair WR, Oettgen HF: Bacillus Calmette-Guérin therapy for superficial bladder cancer: A 10-year follow-up. J Urol 1992;147:1020-1023.
39. Kavoussi LR, Torrence RJ, Gillen DP, et al: Results of 6 weekly intravesical bacillus Calmette-Guérin instillations on the treatment of superficial bladder tumours. J Urol 1988;139: 935.
40. Lamm DL, Blumenstein B, Sarosdy M, Grossman B, Crawford ED: Significant long-term patient benefit with BCG maintenance therapy. A. SWOG study. J Urol 1997;157:213.
41. Lamm DL: Long-term results of intravesical therapy tor superficial bladder cancer. J Clin North Am 1992;19:573-580.
42. Marth D, Studer UE, Ackermann D, Zingg EJ: Primäre Therapieversager nach intravesikalem BCG wegen Carcinoma in situ erlauben kein expektives Verhalten. Urologe [A] 1991; 30(suppl):A71.
43. Wirth M: Therapie des T1 G3 Urothelkarzinoms der Harnblase - Ergebnisse einer Umfrage. Persönliche Mitteilung.
44. Smith JA Jr, Whitmore WF Jr: Regional lymph node metastases from bladder cancer. J Urol 1981;126:591-593.
45. Stöckle M, Alken P, Engelmann U, Jacobi GH, Riedmiller H, Hohenfellner R: Radical cystectomy - often too late. Eur Urol 1986;13:361-367
46. Malkowicz SB, Nichols P, Lieskovsky G, Boyd SD, Huffmann J, Skinner DG: The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2). J Urol 1990;144:641.
47. Brendler CB, Steinberg GD, Marshall FF, Mostwin JL, Walsh PC: Local recurrence and survival following nerve sparing radical cystprostatectomy. J Urol 1990;144:1137.
48. Thüroff JW, Alken P, Riedmiller H, Jacobi GH, Hohenfellner R: 100 cases of Mainz pouch: Continuing experience and evolution. J Urol 1988;140:283-238.
49. Skinner DG, Lieskovsky G, Boyd S: Continent urinary diversion. J Urol 1988;141:1323-1327.
50. Krege S, Giani G, Meyer R, et al: A randomized multicentre trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guérin. J Urol 1996; 156:962-966
51. Vegt PDJ, Witjes A, Debruyne F, Meijden A: A randomized study of intravesical MMC, BCG-tice and BCG-RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol 1995;153:929-933.